Robert A Lasser

Summary

Publications

  1. ncbi request reprint Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder
    Robert A Lasser
    Janssen Medical Affairs, LLC, Titusville, New Jersey 08560, USA
    Int J Geriatr Psychiatry 19:898-905. 2004
  2. ncbi request reprint An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study
    Georges M Gharabawi
    Medical Affairs Division, Janssen Pharmaceutica Products, L P, 1125 Trenton Harbourton Road, Titusville, NJ 08560 0200, USA
    Schizophr Res 77:129-39. 2005
  3. ncbi request reprint Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection
    Robert A Lasser
    Global Medical Strategy, Johnson and Johnson Pharmaceutical Services, LLC, Raritan, NJ 08869, USA
    Schizophr Res 77:215-27. 2005
  4. ncbi request reprint Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidone
    Georges M Gharabawi
    Medical Affairs, Janssen Pharmaceutica Inc, Titusville, New Jersey 08560, USA
    Int Clin Psychopharmacol 21:233-40. 2006
  5. ncbi request reprint Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial
    Robert A Lasser
    Janssen Psychiatry, LLC, Titusville, NJ 08560, USA
    Int J Neuropsychopharmacol 8:427-38. 2005
  6. ncbi request reprint Lack of impact of race on the efficacy and safety of long-acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorder
    Natalie Ciliberto
    Medical Services CNS, Medical Affairs Division, Janssen Pharmaceutica, Inc, Titusville, New Jersey 08560, USA
    Int Clin Psychopharmacol 20:207-12. 2005
  7. ncbi request reprint Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): cross-scale comparison in assessing tardive dyskinesia
    Georges M Gharabawi
    Medical Affairs Division, Janssen Pharmaceutica Products, L P, Titusville, NJ 08560, USA
    Schizophr Res 77:119-28. 2005
  8. ncbi request reprint Smokers and nonsmokers equally affected by olanzapine-induced weight gain: metabolic implications
    Robert A Lasser
    CNS Medical Affairs, Janssen Pharmaceutica Products, LP, 1125 Trenton Harbourton Road, Titusville, NJ 08560 0200, USA
    Schizophr Res 66:163-7. 2004
  9. ncbi request reprint Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone
    Robert A Lasser
    Janssen Medical Affairs, LLC 1125 Trenton Harbourton Road, Office A20904, Titusville, NJ 08560 0200, USA
    Eur Psychiatry 19:219-25. 2004
  10. ncbi request reprint Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia
    John Lauriello
    Department of Psychiatry MSC095030, 1 University of New Mexico Health Sciences Center, Albuquerque, NM 87131 001, USA
    Schizophr Res 72:249-58. 2005

Detail Information

Publications19

  1. ncbi request reprint Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder
    Robert A Lasser
    Janssen Medical Affairs, LLC, Titusville, New Jersey 08560, USA
    Int J Geriatr Psychiatry 19:898-905. 2004
    ..Elderly patients are often an underserved population in terms of optimizing treatment outcomes. Long-acting risperidone, the first long-acting injectable atypical antipsychotic, can improve outcomes through continuous medication delivery...
  2. ncbi request reprint An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study
    Georges M Gharabawi
    Medical Affairs Division, Janssen Pharmaceutica Products, L P, 1125 Trenton Harbourton Road, Titusville, NJ 08560 0200, USA
    Schizophr Res 77:129-39. 2005
    ..This analysis assessed TD by defined research criteria in patients receiving long-acting, injectable risperidone...
  3. ncbi request reprint Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection
    Robert A Lasser
    Global Medical Strategy, Johnson and Johnson Pharmaceutical Services, LLC, Raritan, NJ 08869, USA
    Schizophr Res 77:215-27. 2005
    ..Recently proposed criteria for remission (mild or less on multiple core-symptom ratings for at least 6 months) have been applied to a 1-year study of long-acting risperidone injection...
  4. ncbi request reprint Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidone
    Georges M Gharabawi
    Medical Affairs, Janssen Pharmaceutica Inc, Titusville, New Jersey 08560, USA
    Int Clin Psychopharmacol 21:233-40. 2006
    ..Associations were noted between patient-rated quality of life and specific symptom domains, but not insight...
  5. ncbi request reprint Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial
    Robert A Lasser
    Janssen Psychiatry, LLC, Titusville, NJ 08560, USA
    Int J Neuropsychopharmacol 8:427-38. 2005
    ..Psychotic patients considered stable but symptomatic with oral risperidone treatment showed further improvements in symptom ratings and extrapyramidal dysfunction during a year of bi-weekly injections of long-acting risperidone...
  6. ncbi request reprint Lack of impact of race on the efficacy and safety of long-acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorder
    Natalie Ciliberto
    Medical Services CNS, Medical Affairs Division, Janssen Pharmaceutica, Inc, Titusville, New Jersey 08560, USA
    Int Clin Psychopharmacol 20:207-12. 2005
    ..ESRS scores were low throughout the study, and no significant impact of race was observed. Overall rates of AEs were similar among the racial groups. Race did not appear to impact the efficacy and tolerability of long-acting risperidone...
  7. ncbi request reprint Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): cross-scale comparison in assessing tardive dyskinesia
    Georges M Gharabawi
    Medical Affairs Division, Janssen Pharmaceutica Products, L P, Titusville, NJ 08560, USA
    Schizophr Res 77:119-28. 2005
    ....
  8. ncbi request reprint Smokers and nonsmokers equally affected by olanzapine-induced weight gain: metabolic implications
    Robert A Lasser
    CNS Medical Affairs, Janssen Pharmaceutica Products, LP, 1125 Trenton Harbourton Road, Titusville, NJ 08560 0200, USA
    Schizophr Res 66:163-7. 2004
    ..To examine the impact of smoking status on antipsychotic-associated weight gain...
  9. ncbi request reprint Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone
    Robert A Lasser
    Janssen Medical Affairs, LLC 1125 Trenton Harbourton Road, Office A20904, Titusville, NJ 08560 0200, USA
    Eur Psychiatry 19:219-25. 2004
    ..This report examines 50-weeks of long-acting risperidone therapy in patients previously stabilized with conventional depot antipsychotics...
  10. ncbi request reprint Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia
    John Lauriello
    Department of Psychiatry MSC095030, 1 University of New Mexico Health Sciences Center, Albuquerque, NM 87131 001, USA
    Schizophr Res 72:249-58. 2005
    ..5%; P < 0.01). Long-acting risperidone was well tolerated. Long-acting risperidone initiated during inpatient treatment may be an important strategy in improving long-term outcomes among patients with schizophrenia...
  11. ncbi request reprint Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone
    Jim Van Os
    Maastricht University, Maastricht, The Netherlands
    Int Clin Psychopharmacol 19:229-32. 2004
    ....
  12. ncbi request reprint Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness
    Robert A Lasser
    Princeton HealthCare System
    Ann Clin Psychiatry 19:65-71. 2007
    ..Treatment with long-acting injectable risperidone was evaluated in young adults likely to be in the early stages of schizophrenia or schizoaffective disorder...
  13. ncbi request reprint Methodological issues in a comparative study of ziprasidone and risperidone
    Georges M Gharabawi
    J Clin Psychiatry 67:162-3; author reply 163-4. 2006
  14. ncbi request reprint A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder
    George M Simpson
    Department of Psychiatry, Keck School of Medicine of the University of Southern California, Los Angeles, USA
    J Clin Psychiatry 67:1194-203. 2006
    ..This study examined the effects of 2 doses of long-acting risperidone injection in patients with schizophrenia or schizoaffective disorder...
  15. ncbi request reprint Evaluation of a treatment manual for risperidone long-acting injectable
    John P Docherty
    Comprehensive NeuroScience Inc, 21 Bloomingdale Road, White Plains, NY 10605, USA
    Community Ment Health J 43:267-80. 2007
    ..However, in this study manual-supported use of long-acting risperidone was associated with successful implementation of this pharmacologic treatment in the CMHC setting...
  16. ncbi request reprint Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation
    Mark Hyman Rapaport
    Department of Psychiatry, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Neuropsychopharmacology 31:2505-13. 2006
    ..1 and 64.1%, respectively (p < or = 0.05). Open-label risperidone augmentation substantially enhanced response in treatment-resistant patients, but the longer-term benefits of augmentation were not demonstrated in this study...
  17. ncbi request reprint Remission in schizophrenia: proposed criteria and rationale for consensus
    Nancy C Andreasen
    Department of Psychiatry, University of Iowa, Iowa City, Iowa, USA
    Am J Psychiatry 162:441-9. 2005
    ..These criteria should facilitate research and support a positive, longer-term approach to studying outcome in patients with schizophrenia...
  18. ncbi request reprint Measuring remission in schizophrenia: response to Sethuraman et al., 2005
    Mary Kujawa
    Schizophr Res 83:109-10. 2006
  19. ncbi request reprint Remission in schizophrenia: applying recent consensus criteria to refine the concept
    Robert A Lasser
    Neuliance, 12 Penns Trail, Suite 113 Newtown, PA 18940, USA
    Schizophr Res 96:223-31. 2007
    ....